World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
77
Citations
20550
World Ranking
1827
National Ranking
72

Tanja D. de Gruijl publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Tanja D. de Gruijl sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 386 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Tanja D. de Gruijl D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Tanja D. de Gruijl sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 77 D-Index — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Tanja D. de Gruijl is affiliated with Vrije Universiteit Amsterdam in the Netherlands. Their research primarily focuses on medicine and immunology and microbiology, with a significant body of work in oncology and related subfields.

The scientist has contributed extensively to the fields of oncology and immunology, with specific interests including cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, immune cell function and interaction, T-cell and B-cell immunology, immune cells in cancer, and esophageal cancer research and treatment.

Frequent co-authors collaborating with Tanja D. de Gruijl include:

  • Hans van Vliet
  • Rieneke van de Ven
  • Marieke F. Fransen
  • Famke L. Schneiders
  • Roeland Lameris

Their work appears regularly in a range of scientific journals and publication venues. The most frequent venues include:

  • Journal for ImmunoTherapy of Cancer
  • Frontiers in Immunology
  • Cancers
  • Regular and Young Investigator Award Abstracts
  • Clinical & Experimental Immunology

Tanja D. de Gruijl's notable recent publications include:

  • High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy, 2020, Radiology
  • Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT), 2021, Clinical Cancer Research
  • Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future, 2022, Frontiers in Immunology
  • Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  • Pancreatic Cancer and Immunotherapy: A Clinical Overview, 2021, Cancers

Best Publications

  • Functional delivery of viral miRNAs via exosomes

    D. Michiel Pegtel;Katherine Cosmopoulos;David A. Thorley-Lawson;Monique A. J. van Eijndhoven

  • Langerin is a natural barrier to HIV-1 transmission by Langerhans cells.

    Lot de Witte;Alexey Nabatov;Marjorie Pion;Donna Fluitsma

  • Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

    Alfons J M van den Eertwegh;Jurjen Versluis;H Pieter van den Berg;Saskia J A M Santegoets

  • Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

    A. N. Niemeijer;D. Leung;M. C. Huisman;I. Bahce

  • High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy

    Bart Geboers;Hester J Scheffer;Philip M Graybill;Alette H Ruarus

  • Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.

    A. Marijne Heeren;Simone Punt;Maaike C. G. Bleeker;Katja N. Gaarenstroom

  • CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

    Rodney A. Rosalia;Luis J. Cruz;Suzanne van Duikeren;Angelino T. Tromp

  • Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines

    Tanja D. de Gruijl;Alfons J. M. van den Eertwegh;Herbert M. Pinedo;Rik J. Scheper

  • Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation

    Claudia C. Sombroek;Anita G. M. Stam;Allan J. Masterson;Sinéad M. Lougheed

  • Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD40-Targeted Adenoviral Vector

    Bryan W. Tillman;Tanja D. De Gruijl;Sylvia A. Luykx-de Bakker;Rik J. Scheper

  • Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

    Saskia J. A. M. Santegoets;Eveline M. Dijkgraaf;Alessandra Battaglia;Philipp Beckhove

  • The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.

    John P. Veluchamy;Nina Kok;Hans J. van der Vliet;Henk M. W. Verheul

  • Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

    Rodabe N. Amaria;Alexander M. Menzies;Alexander M. Menzies;Alexander M. Menzies;Elizabeth M. Burton;Richard A. Scolyer;Richard A. Scolyer

  • MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors

    Allan J Masterson;Claudia C Sombroek;Tanja D De Gruijl;Yvo M F Graus

  • Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

    Unknown

  • Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients

    J. B. A. G. Haanen;A. Baars;R. Gomez;P. Weder

  • Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells

    Wendy W.J. Unger;Astrid J. van Beelen;Sven C. Bruijns;Medha Joshi

  • Defining the critical hurdles in cancer immunotherapy

    Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  • CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia.

    Johan W. Molling;Tanja D. de Gruijl;Judith Glim;Maria Moreno

  • Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.

    Inge S. van Houdt;Berbel J.R. Sluijter;Laura M. Moesbergen;Wim M. Vos

  • Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c + Dendritic Cell Frequency Predicts Progression-Free Survival

    Hester van Cruijsen;Astrid A.M. van der Veldt;Laura Vroling;Dinja Oosterhoff

Frequent Co-Authors

Rik J. Scheper
Rik J. Scheper Amsterdam University Medical Centers
Henk M.W. Verheul
Henk M.W. Verheul Radboud University
Ekaterina S. Jordanova
Ekaterina S. Jordanova Vrije Universiteit Amsterdam
Yvette van Kooyk
Yvette van Kooyk Vrije Universiteit Amsterdam
George L. Scheffer
George L. Scheffer VU University Medical Center
Susan Gibbs
Susan Gibbs Vrije Universiteit Amsterdam
David T. Curiel
David T. Curiel Washington University in St. Louis
Sybren L. Meijer
Sybren L. Meijer University of Amsterdam
Akseli Hemminki
Akseli Hemminki University of Helsinki
Gerrit Jansen
Gerrit Jansen Amsterdam UMC

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in pursuing Immunology in the USA, exploring complementary healthcare degrees can expand career opportunities. Nursing roles, particularly Licensed Practical Nurse (LPN) and Nurse Practitioner (NP) pathways, often intersect with immunology in clinical settings.

Students seeking accessible entry points may find value in programs recognized as the which lpn programs are easiest to get into. These options help build foundational skills quickly, opening doors to immunology-related patient care roles.

For advanced practice, identifying the easiest np programs to get into can streamline progression while maintaining quality education standards. These degrees prepare graduates for more specialized clinical responsibilities.

Specialization in mental health is a significant area of growth within healthcare. The best psychiatric mental health nurse practitioner programs online offer excellent clinical placement rates, ensuring practical experience to support immunology applications in psychiatric care.

Budget-conscious students can consider the cheapest psychiatric nurse practitioner programs, which provide cost-effective routes to certification without compromising educational quality.

Overall, exploring these related degrees can complement immunology studies and enhance healthcare career prospects.

Best Scientists Citing Tanja D. de Gruijl

Trending Scientists

Recently Published Articles